Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: Biometric parameters and serum DPPIV activity in sham and HF rats treated with vehicle (HF) or vildagliptin for 4 weeks .

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques: Activity Assay

Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: Treatment with vildagliptin improves cardiac function in rats with established HF . Doppler echocardiography and quantitative determination of serum BNP were performed 6 weeks after LV-radiofrequency ablation or sham surgery (pretreatment) and after 4 weeks of treatment with vehicle or vildagliptin (post-treatment). (A) Fractional area change (FAC). (B) Isovolumic relaxation time (IVRT). (C) Serum BNP 32 levels. Values are means ± SEM. # p < 0.05 and ### p < 0.001 vs. pretreatment.

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques:

Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: DPPIV inhibition attenuates cardiac remodeling and capillary rarefaction in rats with established HF. (A) Myocardial hypertrophy was assessed in HF rats treated with vehicle (HF) or vildagliptin (HF + IDPPIV) by measuring cardiomyocyte nuclear volumes in heart sections treated with stained with hematoxylin-eosin (400 × original magnification). (B) Cardiac interstitial fibrosis was evaluated in heart sections stained with picrosirius red (200 × original magnification). (C) Representative immunohistochemical staining of CD31 in sections of the LV viable wall showing individual capillaries (small dark circles) (400 × original magnification). n = 7–9 rats/group. Values are means ± SEM. ** p < 0.01 and *** p < 0.001 vs. Sham. # p < 0.05 and ### p < 0.001 vs. HF.

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques: Inhibition, Staining, Immunohistochemical staining

Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: Heart DPPIV activity and expression in sham and HF rats treated with the DPPIV inhibitor vildagliptin or with the vehicle. (A) Heart DPPIV activity was measured in sham and HF rats treated with vehicle (HF) or vildagliptin (HF + IDPPIV) by colorimetry. (B) Representative immunohistochemical staining of DPPIV in the heart (400 × original magnification). (C) Graphical representation of the relative gene expression of DPPIV in the heart of sham and HF rats treated with vildagliptin or with the vehicle. The levels of mRNA of DPPIV were measured by real-time PCR and cyclophilin used as an internal control. Values are means ± SEM. ** p < 0.01 and *** p < 0.001 vs. Sham. ### p < 0.001 vs. HF.

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques: Activity Assay, Expressing, Colorimetric Assay, Immunohistochemical staining, Staining, Gene Expression, Real-time Polymerase Chain Reaction, Control

Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: Renal DPPIV activity and expression in sham and HF rats treated with the DPPIV inhibitor vildagliptin or with the vehicle. (A) Renal DPPIV activity was measured in sham and HF rats treated with vehicle (HF) or vildagliptin (HF + IDPPIV) by colorimetry. (B) Renal cortical DPPIV abundance was evaluated by immunoblotting. Equal amounts of protein (10 μg for DPPIV and 5 μg for actin) were subjected to SDS-PAGE, transferred to a PVDF membrane and incubated with the following primary antibodies: anti-DPPIV (1:1000) and anti-actin (1:50,000). Membranes were stained with Ponceau S prior to antibody incubation, and the Actin was used as an internal control. Values are means ± SEM. ## p < 0.01 vs. HF.

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques: Activity Assay, Expressing, Colorimetric Assay, Western Blot, SDS Page, Membrane, Incubation, Staining, Control

Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: DPPIV inhibition increases active GLP-1 serum concentration as well as renal cortical GLP-1R expression and PKA activation in HF rats. (A) Serum levels of active GLP-1 were determined by ELISA in sham and HF rats treated with vildagliptin (HF + IDPPIV) or vehicle (HF). (B) Fasting glucose serum levels in sham, HF rats and HF rats treated with vildagliptin. n = 11–17 rats/group (A,B) . (C) Levels of phosphorylation of PKA substrates in the renal cortex of Sham, HF and HF rats treated with vildagliptin (HF + IDPPIV) were evaluated by immunoblotting using an antibody that recognizes proteins containing a phospho-Ser/Thr. Top: Equal amounts of protein (25 μg) from each rat were subjected to SDS-PAGE, transferred to a PVDF membrane and incubated with the antibody anti-pSer/Thr. Actin was used as an internal control. Bottom: The sum total of all phospho-PKA proteins per lane was estimated by densitometry and normalized by actin. The combined data from 6 experiments are represented as columns in a bar graph. Values are means ± SEM. *** p < 0.001 vs. Sham. ### p < 0.001 vs. HF.

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques: Inhibition, Concentration Assay, Expressing, Activation Assay, Enzyme-linked Immunosorbent Assay, Phospho-proteomics, Western Blot, SDS Page, Membrane, Incubation, Control

Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: Treatment with vildagliptin increases NHE3 phosphorylation at the PKA consensus site serine 552 in the renal cortex of HF rats. (A) Representative immunoblotting of renal cortical proteins probed with a phosphospecific NHE3 mAb that recognizes NHE3 only when it is phosphorylated at serine 552 (PS552-NHE3), total NHE3 mAb or anti-actin. (B) Graphical representation of the relative PS552-NHE3 and (C) total NHE3 levels. The relative abundance of PS552-NHE3 was quantitated by densitometry and expressed as a ratio of PS552-NHE3/total. The combined data from 4 experiments are represented. Values are means ± SEM. * p < 0.05 and *** p < 0.001 vs. Sham. ### p < 0.001 vs. HF.

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques: Phospho-proteomics, Western Blot

Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: DPPIV inhibition by vildagliptin improves renal handling of sodium and water of HF rats . Sham and HF rats treated with vildagliptin (HF + IDPPIV) or vehicle (HF) were individually placed into metabolic cages for 24-h urine collection for three consecutive days to evaluate (A) urinary flow and (B) urinary Na + excretion. (C) Water and food consumption were measured daily. (D) Sodium intake was calculated based on the sodium content of the rodent chow and on the daily consumption of chow by each rat. (E) Water and (F) sodium balance. n = 11–17 rats/group. Values are means ± SEM. ** p < 0.01 and *** p < 0.001 vs. Sham. # p < 0.05, ## p < 0.01, ### p < 0.001 vs. HF.

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques: Inhibition

Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: DPPIV inhibition improves GFR and reduces proteinuria in HF rats. (A) The glomerular filtration rate (GFR) was estimated by the creatinine clearance. (B) Urine protein to creatinine ratio. n = 11–17 rats/group. (C) Profile of urinary proteins excreted by sham and HF rats treated with vehicle (HF) or vildagliptin (HF + IDPPV). The 24-h urine samples (volume equivalent to 25 μg of creatinine) were subjected to 10% SDS-PAGE. Following electrophoresis, the gels were silver stained using the ProteoSilver Plus Kit (Sigma-Aldrich). (D) Graphic representation of the amount of intact albumin semiquantitatively evaluated by densitometry. n = 6 rats/group. Values are means ± SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. Sham. # p < 0.05, ## p < 0.01 vs. HF.

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques: Inhibition, Filtration, SDS Page, Electrophoresis, Staining

Journal: Frontiers in Physiology

Article Title: Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

doi: 10.3389/fphys.2016.00293

Figure Lengend Snippet: The antiproteinuric effects of DPPIV inhibition are associated with upregulation of megalin, nephrin, and podocin expressions in the kidneys of HF rats . Equal amounts of renal cortical proteins isolated from sham and HF rats treated with vildagliptin (HF + IDPPIV) or vehicle (HF) (10 μg for megalin and cubilin, 30 μg for nephrin and podocin and 5 μg for actin) were subjected to SDS-PAGE, transferred to a PVDF membrane and incubated with primary antibodies against (A) megalin (1:50,000), (B) cubilin (1:1000), (C) nephrin (1:11,000), or (D) podocin (1:11,000). Actin was used as an internal control. Values are means ± SEM. * p < 0.05 and ** p < 0.01 vs. Sham. # p < 0.05, ### p < 0.001 vs. HF.

Article Snippet: The dipeptidyl peptidase IV (DPPIV) inhibitor vildagliptin was a gift from Novartis Pharmaceuticals (Basel, Switzerland).

Techniques: Inhibition, Isolation, SDS Page, Membrane, Incubation, Control

Journal: Oncoimmunology

Article Title: Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration

doi: 10.1080/2162402X.2023.2268257

Figure Lengend Snippet: Vildagliptin sensitizes radiotherapy.

Article Snippet: Vildagliptin (LAF-237, DPP4 inhibitor) and anti-CD8 antibody were purchased from Selleck.

Techniques:

Journal: Oncoimmunology

Article Title: Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration

doi: 10.1080/2162402X.2023.2268257

Figure Lengend Snippet: Combination of vildagliptin and IR promotes T cell infiltration.

Article Snippet: Vildagliptin (LAF-237, DPP4 inhibitor) and anti-CD8 antibody were purchased from Selleck.

Techniques:

Journal: Oncoimmunology

Article Title: Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration

doi: 10.1080/2162402X.2023.2268257

Figure Lengend Snippet: Vildagliptin sensitizes the combination of radiotherapy and immunotherapy.

Article Snippet: Vildagliptin (LAF-237, DPP4 inhibitor) and anti-CD8 antibody were purchased from Selleck.

Techniques: